Treatment of murine disseminated candidiasis with L-743,872 | Zendy

J R Graybill | Zendy; Laura K. Najvar | Zendy; Michael Luther | Zendy; Annette W. Fothergill | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of murine disseminated candidiasis with L-743,872

Author(s) -

J R Graybill,

Laura K. Najvar,

Michael Luther,

Annette W. Fothergill

Publication year - 1997

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.41.8.1775

Subject(s) - candida albicans , fluconazole , body weight , pharmacology , ratón , mycosis , medicine , systemic candidiasis , corpus albicans , microbiology and biotechnology , biology , immunology , antifungal

L-743,872 (M991), which is a pneumocandin derivative, was evaluated in a mouse model of disseminated candidiasis caused by a fluconazole-resistant isolate of Candida albicans. In immunocompetent mice M991 prolonged survival at doses as low as 0.0125 mg/kg of body weight per day. In neutropenic mice 0.05 mg/kg was the lowest effective dose. M991 is a very potent drug for treatment of disseminated candidiasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research